Physician profile
Daniel Churgin
NPI 1558629550
$15,370.45
in general payments reported to CMS, 2019-2025
17 companies · $966 in 2025
The $966 reported for 2025 was more than what 76% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,166 · 2021: $159 · 2022: $464 · 2023: $7,323 · 2024: $292 · 2025: $966.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Food and Beverage: $1,942 · Consulting Fee: $1,375 · Travel and Lodging: $751 · Education: $12.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Food and Beverage | $1,941.75 |
| Consulting Fee | $1,375.00 |
| Travel and Lodging | $751.17 |
| Education | $12.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,865.63 | 2019-2021 | |
| Alcon Vision LLC | $5,559.12 | 2021-2024 | Constellation |
| Regeneron Pharmaceuticals, INC. | $1,529.46 | 2023-2025 | Eylea, Eylea Hd |
| Astellas Pharma US INC | $290.68 | 2023-2025 | Izervay |
| Rxsight INC | $239.44 | 2023-2024 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $216.31 | 2022-2024 | Xipere |
| Regeneron Healthcare Solutions, INC. | $215.26 | 2021-2025 | Eylea Hd |
| Genentech USA, INC. | $208.38 | 2022-2025 | Vabysmo |
| Harrow Eye, LLC | $173.06 | 2025 | Iheezo, Verkazia, Flarex |
| Eyevance Pharmaceuticals LLC | $170.73 | 2019 | |
| Abbvie INC. | $161.73 | 2025 | |
| Mallinckrodt Enterprises LLC | $141.72 | 2019 | |
| Genentech, INC. | $135.10 | 2023 | Vabysmo, Susvimo |
| Apellis Pharmaceuticals, INC. | $123.40 | 2023 | Syfovre |
| Dutch Ophthalmic, USA | $119.89 | 2024 | Tissueblue, Eva, Combined Machine |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $115.37 | 2025 | Oxervate |
| Sight Sciences, INC. | $105.17 | 2025 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Churgin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.